Suggestions
Rob Woodman
Partner @ Panakes
Rob Woodman is a highly experienced professional in the biotech and pharmaceutical industry, currently serving as a Non Executive Director at Enterprise Therapeutics.4 His career spans various roles in venture capital and investment firms focused on life sciences and healthcare.
Professional Background
Dr. Woodman has been leading the Biotech team at Panakes Partners since 2021.12 He brings global experience in biotech gained from both institutional and corporate venture firms, encompassing investments from early-stage startups to growth-stage companies.1
Previous Positions
Before joining Panakes, Dr. Woodman held several notable positions:
- Senior Partner at Takeda Ventures, where he helped build the investment team and portfolio1
- Head of Genesis Labs, Takeda's internal concept incubator1
- Director of Healthcare Investments at Touchstone Innovations (formerly Imperial Innovations) in London15
- Principal in the life science team at Sofinnova Partners, a leading European venture capital firm1
Achievements
Throughout his career, Dr. Woodman has demonstrated a track record of value creation, as evidenced by multiple acquisitions and NASDAQ listings of companies he has invested in.1 Some of his notable investments include:
- Emendo Bio (acquired by Anges Pharma)
- BioMx Inc (NASDAQ: PHGE)
- Enterprise Therapeutics (potentiator programme acquired by Roche)
- Inivata (acquired by Neogenomics)
- Ascendis Pharma (NASDAQ: ASND)
- Omthera Inc (acquired by AstraZeneca)
Education
Dr. Woodman holds impressive academic credentials:
- PhD in Oncology from the University of Cambridge
- MSc in Biochemistry from the University of Oxford1
His educational background provides him with expertise in Oncology, Cancer Biology, Biochemistry, and Molecular Biology.
Current Role at Enterprise Therapeutics
As a Non Executive Director at Enterprise Therapeutics, Dr. Woodman brings his extensive experience in biotech investments and drug development to support the company's growth and strategic decisions.24 He joined the board following a £26 million Series B follow-on financing round led by Panakes Partners in January 2024.3
